URGENT UPDATE: Pfizer’s U.S. sales of its COVID-19 vaccine, Comirnaty, have plummeted by 25%, dropping to $870 million in the third quarter of 2023. This dramatic decline follows new federal guidance that limits recommendations on who should receive the vaccine, creating confusion among consumers and impacting vaccination rates.
Latest reports confirm that the Centers for Disease Control and Prevention (CDC) has shifted its stance, no longer recommending COVID-19 shots for all Americans. Instead, they now leave the decision to individual patients. This change, announced last month, comes after significant influence from U.S. Health Secretary Robert F. Kennedy Jr., who has expressed skepticism about the safety of vaccines. Previously, health officials had advised annual boosters for everyone aged six months and older.
In a landscape already marked by declining interest in COVID-19 vaccinations, the latest guidance is expected to further diminish uptake this fall. Experts warn that anti-vaccine sentiment and growing uncertainty regarding the necessity of vaccinations could deter many Americans from seeking protection against the virus.
With the fall vaccination season underway, many pharmacies are experiencing a surge in questions from patients. For instance, Theresa Tolle, owner of Bay Street Pharmacy in Sebastian, Florida, reports heightened confusion among her customers. “There are just so many messages out there, they don’t know who to believe,” she stated. Despite the demand from her older patients, she has also encountered a notable increase in customers opting out of the shots this year.
Pfizer’s sales drop contrasts sharply with earlier trends in 2023, where vaccine sales had risen in the first two quarters. Analysts predict that Moderna will also face a significant decline, with expected sales of its Spikevax shots falling by about 50% in the same quarter.
The updated recommendations have led to logistical challenges as well. Some pharmacies initially required prescriptions for the updated vaccines or inquired about patients’ health conditions. However, CVS Health has since confirmed it will not require prescriptions, aiming to simplify access.
The emotional impact of these changes is profound, with many individuals feeling uncertain about their health choices. As the CDC’s recommendations continue to evolve, it remains crucial for consumers to stay informed about their options.
As we approach the winter months, experts underscore the importance of maintaining vaccination rates to protect vulnerable populations. The situation remains fluid, and stakeholders are closely monitoring how these changes affect public health.
WHAT’S NEXT: The upcoming reports from Moderna, set to release their third-quarter results on October 26, 2023, will provide further insight into the vaccine market’s trajectory and consumer response.
Stay tuned for further updates as this developing story unfolds.